Stocks · News reference

HC Wainwright & Co. Reiterates Buy on Upstream Bio, Maintains $36 Price Target

Sep 2, 2026, 11:25 AMBenzinga Newsdesk

HC Wainwright & Co. analyst Matthew Caufield reiterates Upstream Bio (NASDAQ:UPB) with a Buy and maintains $36 price target.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaSep 1, 2026, 11:06 AMBenzinga Newsdesk
Upstream Bio Announces Phase 3 Plans For Verekitug At 400 mg Every 12 Weeks In Severe Asthma And CRSwNP, With About 1,500 Patients Across Two Placebo-Controlled Trials; On Track To Initiate Q1 2027
UPB
SEC EDGARSep 1, 2026, 11:05 AMSEC EDGAR
8-K filing — Upstream Bio, Inc. (UPB)
Filed: 2026-09-01 AccNo: 0001193125-26-377485 Size: 238 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
UPB
BenzingaAug 14, 2026, 4:14 PMBenzinga Newsdesk
JP Morgan Maintains Neutral on Upstream Bio, Raises Price Target to $9
JP Morgan analyst Tessa Romero maintains Upstream Bio (NASDAQ:UPB) with a Neutral and raises the price target from $8 to $9.
UPB